💡 ASCO GI spotlight: CheckMate-8HW shows strong data for Ipi/Nivo in MSI-H CRC — but do we really need to give dual checkpoint to everyone?
https://t.co/YsZlaJOY8J
💥 Promising results from IMA203 TCR therapy targeting PRAME in solid tumors—56% ORR in advanced melanoma! Phase 3 SUPRAME trial now enrolling. A big leap forward in solid tumor cell therapy. #ASCO25#Immunotherapy#Melanoma#CellTherapy#OncologyResearch
https://t.co/RyS3FiREEE
🌪️ Hurricane Milton is approaching! Cancer patients, be sure to: 💊 Stock up on meds 🏥 Contact your care team ⛑️ Know your hospital's emergency plans. Stay safe!
https://t.co/BbOofa1a32